Tag: Cytomegalovirus

Transplant recipients are on immunosuppressive medications to prevent organ rejection, which makes them more vulnerable to infections and other complications. This is why the question 'Do transplant patients get fevers?' is so crucial, as fever is a primary indicator of a serious underlying problem and requires immediate medical attention.

Between 20% and 60% of solid organ transplant recipients develop a symptomatic cytomegalovirus (CMV) infection, a condition valganciclovir is designed to combat [1.10.1]. So, **what is the classification of valganciclovir?** This medication is an antiviral prodrug used to treat and prevent CMV infections [1.2.1, 1.2.2].

First approved by the FDA in 2001, valganciclovir is a highly effective antiviral drug that serves as a prodrug for ganciclovir and is used to treat and prevent cytomegalovirus (CMV) infections. This oral medication offers a convenient alternative to intravenous ganciclovir for controlling CMV-related illnesses, especially in immunocompromised patients.